Thalidomide and lenalidomide for the treatment of refractory dermatologic conditions - 21/06/16
Doi : 10.1016/j.jaad.2016.03.022
Zachary Nahmias, MD a, Vinod E. Nambudiri, MD, MBA b, c, Ruth Ann Vleugels, MD, MPH b, ⁎ 
a Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
b Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts
c Department of Medicine, Grand Strand Regional Medical Center, Myrtle Beach, South Carolina
∗Correspondence to: Ruth Ann Vleugels, MD, MPH, Department of Dermatology, Brigham and Women's Hospital, 221 Longwood Ave, Boston, MA 02115Department of DermatologyBrigham and Women's Hospital221 Longwood AveBostonMA02115
| Drs Nambudiri and Vleugels are co-last authors. |
|
| Dr Vleugels is supported by a Medical Dermatology Career Development Award from the Dermatology Foundation. |
|
| Conflicts of interest: None declared. |
© 2016
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 75 - N° 1
P. 210-212 - juillet 2016 Retour au numéro
Article précédent
- End points in dermatologic clinical trials: A review for clinicians
- Erin X. Wei, Robert S. Kirsner, William H. Eaglstein
- Topically applied ascorbic acid solution for the treatment of basal cell carcinoma (BCC)
- Péter Holló, Hajnalka Jókai, Judit Hársing, Gyöngyvér Soós, Sarolta Kárpáti, Krisztián Németh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?